{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["24(1)"],"submitter":["Zhang Y"],"pubmed_abstract":["<h4>Background</h4>Evolocumab has shown significant reductions in low-density lipoprotein cholesterol (LDL-C) levels and incident cardiovascular events among acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). Nonetheless, the potential modification of evolocumab's effectiveness by baseline inflammatory risk remains unclear. We aimed to assess evolocumab's effectiveness based on baseline neutrophil-to-lymphocyte ratio (NLR) and evaluate residual inflammatory and cholesterol-related risks across varying on-treatment NLR and LDL-C levels.<h4>Methods</h4>This multicentric, retrospective analysis enrolled consecutive patients with ACS undergoing PCI and exhibiting elevated LDL-C at the First Affiliated Hospital of Zhengzhou University and Zhongda Hospita"],"journal":["Lipids in health and disease"],"pagination":["123"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11956451"],"repository":["biostudies-literature"],"pubmed_title":["Effects of residual inflammatory and cholesterol risks on cardiovascular events with evolocumab in patients with acute coronary syndrome undergoing percutaneous coronary intervention."],"pmcid":["PMC11956451"],"pubmed_authors":["Liu H","Chen K","Zhang Y","Bo X","Li K","Xiao T","Ding J","Villamil OIRC"],"additional_accession":[]},"is_claimable":false,"name":"Effects of residual inflammatory and cholesterol risks on cardiovascular events with evolocumab in patients with acute coronary syndrome undergoing percutaneous coronary intervention.","description":"<h4>Background</h4>Evolocumab has shown significant reductions in low-density lipoprotein cholesterol (LDL-C) levels and incident cardiovascular events among acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). Nonetheless, the potential modification of evolocumab's effectiveness by baseline inflammatory risk remains unclear. We aimed to assess evolocumab's effectiveness based on baseline neutrophil-to-lymphocyte ratio (NLR) and evaluate residual inflammatory and cholesterol-related risks across varying on-treatment NLR and LDL-C levels.<h4>Methods</h4>This multicentric, retrospective analysis enrolled consecutive patients with ACS undergoing PCI and exhibiting elevated LDL-C at the First Affiliated Hospital of Zhengzhou University and Zhongda Hospita","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2025-06-28T03:05:32.311Z","creation":"2025-06-28T03:05:32.311Z"},"accession":"S-EPMC11956451","cross_references":{"pubmed":["40165297"],"doi":["10.1186/s12944-025-02537-2"]}}